PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2006 September; 7(3): E61–E69.
Published online 2006 August 4. doi:  10.1208/pt070364
PMCID: PMC2750506

Evaluation of alternative strategies to optimize ketorolac transdermal delivery

Abstract

In the present study, 2 alternative strategies to optimize ketorolac transdermal delivery, namely, prodrugs (polyoxyethylene glycol ester derivatives, I–IV) and nanostructured lipid carriers (NLC) were investigated. The synthesized prodrugs were chemically stable and easily degraded to the parent drug in human plasma. Ketorolac-loaded NLC with high drug content could be successfully prepared. The obtained products formulated into gels showed a different trend of drug permeation through human stratum corneum and epidermis. Particularly, skin permeation of ester prodrugs was significantly enhanced, apart from ester IV, compared with ketorolac, while the results of drug release from NLC outlined that these carriers were ineffective in increasing ketorolac percutaneous absorption owing to a higher degree of mutual interaction between the drug and carrier lipid matrix. Polyoxyethylene glycol esterification confirmed to be a suitable approach to enhance ketorolac transdermal delivery, while NLC seemed more appropriate for sustained release owing to the possible formation of a drug reservoir into the skin.

Keywords: ketorolac, lipid carrier, NLC, prodrug, transdermal delivery

Full Text

The Full Text of this article is available as a PDF (203K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Kokki H. Nonsteroidal anti-inflammatory drugs for postoperative pain: a focus on children. Paediatr Drugs. 2003;5:103–123. [PubMed]
2. Buckley MM, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990;39:86–109. doi: 10.2165/00003495-199039010-00008. [PubMed] [Cross Ref]
3. Reinhart DI. Minimizing the adverse effects of ketorolac. Drug Saf. 2000;22:487–497. doi: 10.2165/00002018-200022060-00007. [PubMed] [Cross Ref]
4. Parikh DK, Ghosh TK. Feasibility of transdermal delivery of fluoxetine. AAPS PharmSciTech. 2005;6:E144–E149. doi: 10.1208/pt060222. [PMC free article] [PubMed] [Cross Ref]
5. Doh HJ, Cho WJ, Yong CS, et al. Synthesis and evaluation of ketorolac ester prodrugs for transdermal delivery. J Pharm Sci. 2003;92:1008–1017. doi: 10.1002/jps.10353. [PubMed] [Cross Ref]
6. Foldvari M. Non-invasive administration of drugs through the skin: challenges in delivery system design. Pharm Sci Technol Today. 2000;3:417–425. doi: 10.1016/S1461-5347(00)00317-5. [PubMed] [Cross Ref]
7. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101–114. doi: 10.1016/S0928-0987(01)00167-1. [PubMed] [Cross Ref]
8. Alsarra IA, Bosela AA, Ahmed SM, Mahrous GM. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm. 2005;59:485–490. doi: 10.1016/j.ejpb.2004.09.006. [PubMed] [Cross Ref]
9. Cho YA, Gwak HS. Transdermal delivery of ketorolac tromethamine: effects of vehicles and penetration enhancers. Drug Dev Ind Pharm. 2004;30:557–564. doi: 10.1081/DDC-120037486. [PubMed] [Cross Ref]
10. Tiwari SB, Udupa N. Investigation into the potential of iontophoresis facilitated delivery of ketorolac. Int J Pharm. 2003;260:93–103. doi: 10.1016/S0378-5173(03)00249-7. [PubMed] [Cross Ref]
11. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177. doi: 10.1016/S0939-6411(00)00087-4. [PubMed] [Cross Ref]
12. Kim BY, Doh HJ, Le TN, et al. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies. Int J Pharm. 2005;293:193–202. doi: 10.1016/j.ijpharm.2005.01.002. [PubMed] [Cross Ref]
13. Bonina FP, Montenegro L, Caprariis P, Palagiano F, Trapani G, Liso G. In vitro and in vivo evaluation of polyoxyethylene indomethacin esters as dermal prodrugs. J Control Release. 1995;34:223–232. doi: 10.1016/0168-3659(95)00003-Q. [Cross Ref]
14. Inagi T, Muramatsu T, Nagai H, Terada H. Mechanism of indomethacin partition between n-octanol and water. Chem Pharm Bull (Tokyo) 1981;29:2330–2337.
15. Niwa T, Takeuchi H, Hino T, Kunou N, Kawashima Y. Preparation of biodegradable nanospheres of water-soluble and insoluble drugs with D,L-lactide/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J Control Release. 1993;25:89–98. doi: 10.1016/0168-3659(93)90097-O. [Cross Ref]
16. Kligman AM, Christophers E. Preparation of isolated sheets of human stratum corneum. Arch Dermatol. 1963;88:702–705. [PubMed]
17. Swarbrick J, Lee G, Brom J. Drug permeation through human skin: I. Effect of storage conditions of skin. J Invest Dermatol. 1982;78:63–66. doi: 10.1111/1523-1747.ep12497937. [PubMed] [Cross Ref]
18. Bronaugh RL, Stewart RF, Simon M. Methods for in vitro percutaneous absorption studies VII: use of excised human skin. J Pharm Sci. 1986;75:1094–1097. doi: 10.1002/jps.2600751115. [PubMed] [Cross Ref]
19. Touitou E, Fabin B. Altered skin permeation of a highly lipophilic molecule: tetrahydrocannabinol. Int J Pharm. 1988;43:17–22. doi: 10.1016/0378-5173(88)90053-1. [Cross Ref]
20. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2003;4:E7–E7. doi: 10.1208/pt040107. [PMC free article] [PubMed] [Cross Ref]
21. Bonina FP, Puglia C, Barbuzzi T, et al. In vitro and in vivo evaluation of polyoxyethylene esters as dermal prodrugs of ketoprofen, naproxen and diclofenac. Eur J Pharm Sci. 2001;14:123–134. doi: 10.1016/S0928-0987(01)00163-4. [PubMed] [Cross Ref]
22. Goldsmith LA. Physiology, Biochemistry, and Molecular Biology of the Skin. New York, NY: Oxford University Press; 1991.
23. Yalkowsky SH, Valvani SC. Solubility and partitioning I: solubility of nonelectrolytes in water. J Pharm Sci. 1980;69:912–922. doi: 10.1002/jps.2600690814. [PubMed] [Cross Ref]
24. Yalkowsky SH, Valvani SC, Roseman TJ. Solubility and partitioning VI: octanol solubility and octanol-water partition coefficients. J Pharm Sci. 1983;72:866–870. doi: 10.1002/jps.2600720808. [PubMed] [Cross Ref]
25. Osborne DW. Computational methods for prodrug or drug analogue selection optimized for percutaneous delivery. In: Osborne DW, Amann AH, editors. Topical Drug Delivery Formulations. New York, NY: Marcel Dekker; 1990. pp. 109–125.
26. Foroutan SM, Watson DG. Synthesis and characterization of polyethylene glycol conjugates of hydrocortisone as potential prodrugs for ocular steroid delivery. Int J Pharm. 1997;157:103–111. doi: 10.1016/S0378-5173(97)00236-6. [Cross Ref]
27. Ricci M, Puglia C, Bonina F, Giovanni C, Giovagnoli S, Rossi C. Evaluation of indomethacin percutaneous absorption from nanostructured lipid carriers (NLC): in vitro and in vivo studies. J Pharm Sci. 2005;94:1149–1159. doi: 10.1002/jps.20335. [PubMed] [Cross Ref]
28. Davaran S, Rashidi MR, Hashemi M. Synthesis and hydrolytic behavior of 2-mercaptoethyl ibuprofenate-polyethylene glycol conjugate as a novel transdermal prodrug. J Pharm Pharmacol. 2003;55:513–517. doi: 10.1211/002235702900. [PubMed] [Cross Ref]
29. Lien EJ, Gao H. QSAR analysis of skin permeability of various drugs in man as compared to in vivo and in vitro studies in rodents. Pharm Res. 1995;12:583–587. doi: 10.1023/A:1016266316100. [PubMed] [Cross Ref]
30. Bonina FP, Rimoli MG, Avallone L, et al. New oligoethylene ester derivatives of 5-iodo-2′-deoxyuridine as dermal prodrugs: synthesis, physicochemical properties, and skin permeation studies. J Pharm Sci. 2002;91:171–179. doi: 10.1002/jps.1174. [PubMed] [Cross Ref]
31. Castelli F, Puglia C, Sarpietro MG, Rizza L, Bonina F. Characterization of indomethacin loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm. 2005;304:231–238. doi: 10.1016/j.ijpharm.2005.08.011. [PubMed] [Cross Ref]
32. Puglia C, Bonina F, Trapani G, Franco M, Ricci M. Evaluation of in vitro percutaneous absorption of lorazepam and clonazepam from hydroalcoholic gel formulations. Int J Pharm. 2001;228:79–87. doi: 10.1016/S0378-5173(01)00806-7. [PubMed] [Cross Ref]
33. Röpke CD, Kaneko TM, Rodrigues RM, et al. Evaluation of percutaneous absorption of 4-nerolidylcathecol from 4 topical formulations. Int J Pharm. 2002;249:109–116. doi: 10.1016/S0378-5173(02)00477-5. [PubMed] [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists